Bio: Michael N. Tillinger, MD, is currently VP of clinical development at Wave Life Sciences Ltd. and oversees Wave’s portfolio of therapeutic research and development programs with a focus on genetically defined neurodegenerative diseases. Dr. Tillinger is a board certified anesthesiologist with over 20 years of biopharmaceutical industry experience developing therapies across several therapeutic areas including for neurological disorders. Prior to joining Wave in 2022, he served as the VP of clinical development at X4 Pharmaceuticals and was responsible for development strategy and oversight for compounds within rare diseases areas. Dr. Tillinger received his undergraduate degree and medical degree from Sackler School of Medicine at the Tel Aviv University in Israel.